2005年于中国科学院上海药物研究所获得博士学位，现任上海药物研究所研究员、课题组长。从事难治性自身免疫性疾病的新药研发，以及药物干预新靶点和生物标志物的应用基础研究。研制了数个候选新药（1.1类化学药物）进入临床研究，在疾病病理机制和生物标志物研究方面也取得了一定进展，已获国内外专利授权20余项，在SCI期刊上发表论文80余篇。主持国家重大科技专项、国家自然科学基金、上海市科委等项目；获得中国药理学会、上海药理学会、上海药学会等奖项及荣誉。
针对难治性自身免疫性疾病（银屑病、炎症性肠病、慢性肾炎等）和病毒感染性疾病开展创新药物的发现和基础研究。
2013年获得国家“优秀青年基金”
2013年施维雅青年药理学工作者奖
2013年中国药学会科学技术奖二等奖（第二完成人）
2014年获得“中青年科技创新领军人才”称号
2018年获得“上海市三八红旗手”称号
2006年、2013年、2018年 获得上海市科委项目支持
2008年、2012年、2014、2017年 获得新药创制重大专项支持
2011年、2013年、2017年 获得国家自然科学基金支持
2013年 获得国家自然科学基金优秀青年科学基金项目支持
2016年、2019年 获得中国科学院先导科技专项支持
1.Li H, Feng C, Fan C, Yang Y, Yang X, Lu H, Lu Q, Zhu F, Xiang C, Zhang Z, He P, Zuo J, Tang W. Intervention of oncostatin M-driven mucosal inflammation by berberine exerts therapeutic property in chronic ulcerative colitis. Cell Death Dis. 2020 Apr 24;11(4):271.
2.Wu Y, Wu B, Zhang Z, Lu H, Fan C, Qi Q, Gao Y, Li H, Feng C, Zuo J, Tang W. Heme protects intestinal mucosal barrier in DSS-induced colitis through regulating macrophage polarization in both HO-1-dependent and HO-1-independent way. FASEB J. 2020 Apr 17.
3.Li H, Li J, Zhang X, Feng C, Fan C, Yang X, Zhang R, Zhu F, Zhou Y, Xu Y, Liu H, Tang W*. DC591017, a phosphodiesterase-4 (PDE4) inhibitor with robust anti-inflammation through regulating PKA-CREB signaling. Biochem Pharmacol. 2020 Apr 3:113958.
4.Li H, Fan C, Lu H, Feng C, He P, Yang X, Xiang C, Zuo J*, Tang W*.. Protective role of berberine on ulcerative colitis through modulating enteric glial cells-intestinal epithelial cells-immune cells interactions. Acta Pharm Sin B. 2020 Mar;10(3):447-461.
5.Xie Z, Wu B, Liu Y, Ren W, Tong L, Xiang C, Wei A, Gao Y, Zeng L, Xie H*, Tang W*, Hu Y*. Novel Class of Colony-Stimulating Factor 1 Receptor Kinase Inhibitors Based on an o-Aminopyridyl Alkynyl Scaffold as Potential Treatment for Inflammatory Disorders. J Med Chem. 2020 Feb 13;63(3):1397-1414.
6.Lu H, Li H, Fan C, Qi Q, Yan Y, Wu Y, Feng C, Wu B, Gao Y, Zuo JP*, WeiTang*. RIPK1 inhibitor ameliorates colitis by directly maintaining intestinal barrier homeostasis and regulating following IECs-Immuno crosstalk. Biochem Pharmacol. 2020 Feb;172:113751
7.Zhang Z, Wu Y, Wu B, Qi Q, Li H, Lu H, Fan C, Feng C, Zuo J*, Niu L*, Tang W*. DZ2002 ameliorates fibrosis, inflammation, and vasculopathy in experimental systemic sclerosis models. Arthritis Res Ther. 2019 Dec 16;21(1):290.
8.Wu B, Wu YW*, Tang W*. Heme Catabolic Pathway in Inflammation and Immune Disorders. Front. Pharmacol. 2019 Jul 24;10:825.
9.Yang M, Li H, Zhang Q, Wu QH, Li G, Chen KX, Guo YW*, Tang W*, Li XW*. Highly diverse cembranoids from the South China Sea soft coral Sinularia scabra as a new class of potential immunosuppressive agents. Bioorg Med Chem. 2019 Aug 1;27(15):3469-3476.
10.Zhang X, Dong G, Li H, Chen W, Li J, Feng C, Gu Z, Zhu F, Zhang R, Li M, Tang W*, Liu H*, Xu Y*. Structure-Aided Identification and Optimization of Tetrahydro-isoquinolines as Novel PDE4 Inhibitors Leading to Discovery of an Effective Anti-Psoriasis Agent. J Med Chem. 2019 Jun 13;62(11):5579-5593.
11.Li H, Fan C, Feng C, Wu Y, Lu H, He P, Yang X, Zhu F, Qi Q, Gao Y, *Zuo J, *Tang W. Inhibition of phosphodiesterase-4 attenuates murine ulcerative colitis through interference with mucosal immunity. Br J Pharmacol. 2019 Jul;176(13):2209-2226.
12.Li G, Li H, Zhang Q, Yang M, Gu YC, Liang LF*, Tang W*, Guo YW*. Rare Cembranoids from Chinese Soft Coral Sarcophyton ehrenbergi: Structural and Stereochemical Studies. J Org Chem. 2019 May 3;84(9):5091-5098.
13.He S, Liu X, Lin Z, Liu Y, Gu L, Zhou H*, Tang W*, Zuo J*. Reversible SAHH inhibitor protects against glomerulonephritis in lupus-prone mice by downregulating renal -actinin-4 expression and stabilizing integrin-cytoskeleton linkage. Arthritis Res Ther. 2019 Jan 29;21(1):40.
14.Yang M, Liang LF, Li H, Tang W*, Guo YW*. A new 5 ,8 -epidioxysterol with immunosuppressive activity from the South China Sea soft coral Sinularia sp. Nat Prod Res. 2019 Jan 29:1-6.
15.Liu J, Li H, Chen K, Zuo J, Guo YW, Tang W*, Li XW*. Design and Synthesis of Marine Phidianidine Derivatives as Potential Immunosuppressive Agents. J Med Chem. 2018 Nov 30.
16.Wang XF, Li H, Jiang K, Wang QQ, Zheng YH, Tang W*, Tan CH*. Anti-inflammatory constituents from Perilla frutescens on lipopolysaccharide-stimulated RAW264.7 cells. Fitoterapia. 2018 Oct;130:61-65.
17.Li H, Zuo J*, Tang W*. Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases. Front Pharmacol. 2018 Oct 17;9:1048.
18.Yan YX, Shao MJ, Qi Q, Xu YS, Yang XQ, Zhu FH, He SJ, He PL, Feng CL, Wu YW, Li H, Tang W*, Zuo JP*. Artemisinin analogue SM934 ameliorates DSS-induced mouse ulcerative colitis via suppressing neutrophils and macrophages. Acta Pharmacol Sin. 2018 Oct;39(10):1633-1644.
19.Lin ZM, Ma M, Li H, Qi Q, Liu YT, Yan YX, Shen YF, Yang XQ, Zhu FH, He SJ, Tang W*, Zuo JP*. Topical administration of reversible SAHH inhibitor ameliorates imiquimod-induced psoriasis-like skin lesions in mice via suppression of TNF- /IFN- -induced inflammatory response in keratinocytes and T cell-derived IL-17. Pharmacol Res. 2018 Mar;129:443-452.
20.Qi Q, Li H, Lin ZM, Yang XQ, Zhu FH, Liu YT, Shao MJ, Zhang LY, Xu YS, Yan YX, Sun LL, He SJ, Tang W*, Zuo JP*. (5R)-5-hydroxytriptolide ameliorates anti-glomerular basement membrane glomerulonephritis in NZW mice by regulating Fc receptor signaling. Acta Pharmacol Sin. 2018 Jan;39(1):107-116.
